Orthocell Limited
OCC
Rank in Stocks
#19155
Headquartered in Murdoch, Australia, Orthocell Limited, established in 2006,... Headquartered in Murdoch, Australia, Orthocell Limited, established in 2006, operates as a regenerative medicine company focused on creating and bringing to market advanced cell therapies and biological medical devices. These innovations are designed to facilitate the healing of a range of bone and soft tissue injuries. The company's product lineup includes CelGro, a naturally derived collagen medical device engineered to augment surgical repair across various indications, including bone, peripheral nerves, tendons, and cartilage. Another key offering is Ortho-ATI, a specialized cell therapy developed for the treatment of chronic tendon injuries. Furthermore, Orthocell provides Ortho-ACI, an autologous chondrocyte implantation technique aimed at repairing articular cartilage defects in the knee and ankle. Its portfolio also features Striate+, a biodegradable collagen membrane employed for guided bone and tissue regeneration in dental applications, and Remplir, a collagen scaffold utilized for the restoration of peripheral nerves.
Share Price
$0.41531402
Last synced: 2026-11-10
Market Cap
$113.13M
Change (1 day)
0.84%
Change (1 year)
-42.66%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Orthocell Limited (OCC)
Category
Healthcare
EPS for Orthocell Limited (OCC)
EPS as of June 2026 TTM: $-0.04
According to Orthocell Limited's latest financial reports, its current EPS (TTM) is $-0.04. At the end of 2025 the company had an EPS of $-0.03, a decrease compared to its 2024 EPS of $-0.02.
EPS history for Orthocell Limited from 2013 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.04 | 24.67% |
| 2025 | $-0.03 | 6.75% |
| 2024 | $-0.02 | 12.32% |
| 2023 | $-0.02 | -34.67% |
| 2022 | $-0.03 | -11.02% |
| 2021 | $-0.04 | 46.37% |
| 2020 | $-0.02 | -28.53% |
| 2019 | $-0.03 | -14.74% |
| 2018 | $-0.04 | 22.59% |
| 2017 | $-0.03 | 3.75% |
| 2016 | $-0.03 | -16.88% |
| 2015 | $-0.04 | -34.52% |
| 2014 | $-0.06 | 68.00% |
| 2013 | $-0.04 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -41,971.66% |
US
|
|
| $-7.07 | 18,803.74% |
US
|
|
| $-5.29 | 14,044.39% |
AU
|
|
| $12.88 | -34,538.77% |
BE
|
|
| $21.56 | -57,747.06% |
NL
|
Questions about Orthocell Limited's earnings per share (EPS)
What is Orthocell Limited's earnings per share (EPS)?
Orthocell Limited's earnings per share (EPS) over the last twelve months is $-0.04, as of Jun 2026.
What was Orthocell Limited's earnings per share (EPS) in 2025?
In 2025, Orthocell Limited's earnings per share (EPS) was $-0.03, compared with $-0.02 in 2024.
How has Orthocell Limited's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Orthocell Limited's earnings per share (EPS) was highest in 2024 ($-0.02) and lowest in 2021 ($-0.04).
How does Orthocell Limited's earnings per share (EPS) compare with similar companies?
Orthocell Limited's earnings per share (EPS) ($-0.04) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.